BioCentury
ARTICLE | Company News

Five Prime, GlaxoSmithKline deal

November 17, 2014 8:00 AM UTC

The companies added two programs targeting chronic obstructive pulmonary disease (COPD) and refractory asthma to a 2012 deal under which they partnered to identify targets and drug candidates. Five Prime said the additional programs were added in April under a six month evaluation period, which GSK has decided to continue for an additional 18 months. ...